Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Summary: Background: We assessed the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine. Methods: A randomised Phase-1/2 trial followed by a Phase-2 trial were conducted to assess the safety and immunogenicity of the COVID-19 vaccine Corbevax and select to an optimum...

Descrición completa

Detalles Bibliográficos

Principais autores:	Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, Vijay Yerroju, Rammohan Mogulla, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Guruprasad Medigeshi, Janmejay Singh, Heena Shaman, Chandramani Singh, Venkateshwar Rao A
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2022-09-01
Series:	EBioMedicine
Assuntos:	Covid-19 Vaccine Receptor-binding domain SARS-CoV-2 Spike protein Protein subunit
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2352396422003991
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!